160 related articles for article (PubMed ID: 36964635)
1. CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
Zheng X; Chen L; Liu W; Zhao S; Yan Y; Zhao J; Tian W; Wang Y
Hereditas; 2023 Mar; 160(1):13. PubMed ID: 36964635
[TBL] [Abstract][Full Text] [Related]
2. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
4. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
7. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
9. CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma.
Ma G; Yang L; Dong J; Zhang L
Curr Pharm Biotechnol; 2022; 23(9):1168-1178. PubMed ID: 34792009
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.
Zhang C; Zhu Q; Gu J; Chen S; Li Q; Ying L
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072916
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
Pan T; Wang S; Wang Z
J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
[No Abstract] [Full Text] [Related]
14. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
15. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
16. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
17. Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer.
Guo Q; Zhao L; Yan N; Li Y; Guo C; Dang S; Shen X; Han J; Luo Y
Front Immunol; 2023; 14():1148056. PubMed ID: 36993958
[TBL] [Abstract][Full Text] [Related]
18. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
19. Long Non-coding RNA LINC00473 Promotes Breast Cancer Progression
Zhang C; Yang T
Protein Pept Lett; 2023; 30(1):72-84. PubMed ID: 36305147
[TBL] [Abstract][Full Text] [Related]
20. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
